Fennec announces four PEDMARK abstracts accepted at 2026 ASCO meeting

FENNEC PHARMACEUTICALS INC.

Four abstracts evaluating PEDMARK accepted for presentation/publication at the 2026 ASCO Annual Meeting (May 29–June 2, Chicago).
Key poster: STS-J01 study on delayed sodium thiosulfate for cisplatin-induced ototoxicity in pediatric/adolescent patients.
Other posters: randomized phase 1 trial in men with metastatic germ cell tumor; real-world feasibility in young adults; audiometric outcomes in head and neck cancer.
Full abstracts will be available on ASCO website May 21, 2026 at 5:00 p.m. ET.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.